A 62-year-old man is evaluated in the medical intensive care unit. He was admitted 8 days … — USMLE Step 2 CK

A 62-year-old man is evaluated in the medical intensive care unit. He was admitted 8 days ago after suffering an out-of-hospital cardiac arrest and has required continuous mechanical ventilation for airway protection and management of anoxic brain injury. Three days ago, he developed a temperature of $38.8^\circ\text{C}$ ( $101.8^\circ\text{F}$ ), thick purulent secretions from the endotracheal tube, and an increased oxygen requirement. A chest radiograph obtained at that time demonstrated a new right lower lobe consolidation.

He was empirically started on broad-spectrum antimicrobial therapy with vancomycin and cefepime. Today, his clinical condition has significantly improved; he is afebrile, and his oxygenation has stabilized. A quantitative endotracheal aspirate culture obtained prior to antibiotic initiation has returned positive for heavy growth of *Staphylococcus aureus*. Susceptibility testing results are as follows:

Antimicrobial	Interpretation
Cefazolin	Susceptible
Cefepime	Susceptible
Linezolid	Susceptible
Oxacillin	Susceptible
Penicillin	Resistant
Vancomycin	Susceptible

What is the most appropriate next step in the pharmacologic management of this patient?

A
Add linezolid to the current antimicrobial regimen
B
Maintain the current regimen of vancomycin and cefepime
Discontinue vancomycin and cefepime, and initiate cefazolinAnswer
D
Discontinue cefepime and maintain vancomycin monotherapy
E
Discontinue vancomycin and maintain cefepime monotherapy

Answer

Discontinue vancomycin and cefepime, and initiate cefazolin

This patient developed ventilator-associated pneumonia (VAP) and was appropriately started on empiric broad-spectrum antibiotics covering methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* (vancomycin and cefepime). The endotracheal culture has now grown *S. aureus* that is susceptible to oxacillin, meaning it is methicillin-susceptible *Staphylococcus aureus* (MSSA). A core tenet of critical care and infectious disease management is antibiotic stewardship: once culture and susceptibility data are available, broad-spectrum empiric therapy must be de-escalated to targeted, narrow-spectrum therapy. For MSSA pneumonia or bacteremia, narrow-spectrum beta-lactams (such as cefazolin, oxacillin, or nafcillin) are the preferred agents. They provide more rapid bacterial clearance and better clinical outcomes compared to vancomycin. Therefore, the correct management is to discontinue both empiric broad-spectrum agents and initiate targeted therapy with cefazolin.

Step-by-Step Solution

Diagnose the specific infection based on clinical and laboratory data.

The patient developed ventilator-associated pneumonia (VAP) caused by methicillin-susceptible Staphylococcus aureus (MSSA), indicated by the positive culture and susceptibility to oxacillin.

Accurate identification of the pathogen and its resistance profile is required to tailor antimicrobial therapy.

Evaluate the current empiric therapy against the culture results.

The patient is improving on empiric vancomycin and cefepime, but these agents are overly broad given the isolated MSSA.

Empiric therapy is designed to cover a wide array of potential pathogens (e.g., MRSA, Pseudomonas) until specific culture data is available.

Apply the principles of antibiotic stewardship to modify therapy.

Therapy must be de-escalated to a narrow-spectrum agent. Intravenous cefazolin (or nafcillin/oxacillin) is selected, and empiric agents are stopped.

Beta-lactams like cefazolin are the standard of care for MSSA, demonstrating superior bacterial clearance and reduced mortality compared to vancomycin, while also minimizing selective pressure for resistant organisms.

Key Concept

In the management of ventilator-associated pneumonia, empiric broad-spectrum antibiotics should be de-escalated to a targeted, narrow-spectrum agent (e.g., cefazolin or oxacillin for MSSA) once culture and susceptibility results are available. Beta-lactams are superior to vancomycin for treating MSSA infections.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic